Skip to content
Metabolic HealthRecovery & Repair

ATX-304 / O304: following the cell’s energy-sensing response

AMPK connects cellular energy status with fuel use. The O304 research program links this mechanism to glucose handling and perfusion, including a short human proof-of-concept study.

Evidence type
Cell and mouse experiments + 28-day human proof of concept
Provenance
Adapted from RUO
Status
Published 1 November 2026

Adapted with permission from the owner’s reviewed RUO source material. Members-only references are linked below; public research citations support the scientific context.

Identity comes before interpretation

The human proof-of-concept paper uses the name O304. The developer’s program identifies ATX-304 as the later name for that program and cites the O304 publication; the separate 2024 kidney-injury paper uses ATX-304. Keeping those names attached to their actual sources prevents an animal experiment from being mistaken for the human trial.

This is a small-molecule research program, not a peptide. Its connection to the RUO course is AMPK: an enzyme complex that helps cells respond to their energy state by coordinating processes that consume energy with processes that generate it.

A cellular signal with tissue-level consequences

In the O304 experiments, the compound supported AMPK activation by reducing dephosphorylation of its activated form. Downstream changes included phosphorylation of acetyl-CoA carboxylase, a marker connected to fuel metabolism. The proposed relevance extends beyond one marker: altering energy-related signaling may affect glucose uptake, substrate use and the behavior of vascular cells.

The original research included animal findings on glucose handling and microvascular perfusion—the movement of blood through small vessels. The RUO lesson connects those ideas without treating improved perfusion and lower glucose as identical outcomes. A change in either endpoint needs to be measured, not inferred from the word “AMPK.”

A short human study, not the end of the evidence

The published O304 program included a 28-day proof-of-concept study in people with type 2 diabetes receiving metformin. It reported changes in fasting glucose, an insulin-resistance estimate and microvascular measures. That defined setting is more informative than a general “metabolic optimizer” claim, but the short duration cannot establish lasting benefits or uncommon risks.

The later ATX-304 kidney study instead used cultured cells and a cisplatin-injury mouse model. Its AMPK-dependent findings support another mechanistic line of inquiry, not proven kidney protection in people. Together, these sources show why energy-sensing research is promising while preserving the identity and scope of each experiment.

Keywordspan-AMPK · ACC · small molecule · O304 · O-304 · perfusion · glucose

Public research & references

  1. [1]Steneberg et al. (2018). PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. DOI: 10.1172/jci.insight.99114 (opens in a new tab)
  2. [2]The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury (2024). Biomed Pharmacother. PMID: 38749175 (opens in a new tab)
  3. [3]Amplifier Therapeutics. ATX-304 program and former O304 designation; developer source for naming history, not independent efficacy evidence. (opens in a new tab)

Research education, not individualized medical advice.